All News

Key lifestyle risk factors for chronic diseases and cancers include tobacco use, poor nutrition, lack of physical movement, and obesity.

Akram Hussein, PharmD, MBA, BCNP, discusses the treatment process when treating a patient with prostate cancer with a radiopharmaceutical.

Pharmacists on duty decline to dispense the medication to manage COVID-19, raising question about self-determination.

Axicabtagene ciloleucel demonstrated a 2.5-fold increase in individuals with relapsed/refractory large B-cell lymphoma who were alive at 2 years and did not experience either cancer progression or require the need for additional cancer treatment.

More and more data, both from real world analyses and clinical trials, are shedding light on the effective uses of cannabis, as well as the contraindications for its use in patients.

Even the terms themselves, “sex” and “gender,” are often misused and misunderstood by US society and medical professionals alike.

Imminent March, April expiration dates indicate changes are on the horizon for pharmacy services.

Therapy from Karuna Therapeutics demonstrates an 8.4-point reduction in Positive and Negative Syndrome Scale total score compared with the placebo at week 5.

Muneeb Shah, DO, dermatologist and partner at PC Dermatology PLLC, and Reid Maclellan, MD, founder of Cortina Health Inc, tackle misinformation and myths surrounding sun screen, skin cancer, and acne.

An expert suggests that education and agency are significant barriers to care in marginalized communities, which she discusses live with Pharmacy Times at the American Pharmacists Association (APhA) Meeting & Exposition in Phoenix, Arizona from March 24 to 27.

Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, discusses some of the ways that social determinants of health can impact patient health outcomes.

Expert weighs the benefits and pitfalls of social media, the importance of quality information from credible journal sources, and why information that sparks an emotional response can be more influential than evidence-based facts.

Although attention-deficit/hyperactivity disorder (ADHD) is not as common in adults, it can still be present and bothersome, however, adults with ADHD may have learned to hide it a bit better than children.

Prior to the pandemic, the seasonality of respiratory syncytial virus followed a pattern; now, this pattern of disease spread has changed significantly.

Vibhuti Arya, PharmD, MPH, FAPhA, explains how APhA as an organization is opening discourse among its members regarding unpacking and dismantling structural racism in the organization and in the profession at large.

Vibhuti Arya, PharmD, MPH, FAPhA, discusses the role of the individual in progressing structural and systemic changes in the pharmacy ecosystem.

Specifically, non-opioids are often preferred for the management of subacute and chronic pain because of their safety profiles.

Although community oncology has grown, maintaining services for patients is an ongoing challenge.

Presenter at the 2023 Community Oncology Alliance meeting notes that oncology has become more of a duality between molecular and genetic subsets, leading to huge developments in targeted and personalized care.

Pharmacy Times is covering the American Pharmacists Association (APhA) Annual Meeting & Exposition in Phoenix, Arizona from March 24 to 27, 2023.

Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, discusses current outlook on the occurrence of outbreaks of vaccine-preventable diseases in the country.

Specifically, 3 new drugs for sickle cell disease are providing options for patients who are not responding to hydroxyurea.

In addition to improving working conditions for current employees, burnout must be addressed in order to recruit and retain new employees and alleviate understaffing.

Since 2014, 10 immunotherapies have been approved by the FDA, including 6 CAR T-cell therapies and 4 BiTE therapies.

Although state efforts can be impactful, Downs said enforcement is a major hurdle.

Spherix Global Insights estimates that SER-109 (Seres Therapeutics; Aimmune) will be able to challenge fecal microbiota, live-jslm in C. difficile treatment.

Phase 2B clinical trial results demonstrate that patients experienced improvement in total body and facial repigmentation.

Children in the LT-001 study treated after onset achieved or maintained additional milestones up to 7.5 years after 1-time intravenous infusion, Novartis says.

This month, we spoke with expert Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine.

Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.